ID

21837

Description

Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy.; ODM derived from: https://clinicaltrials.gov/show/NCT00305188

Link

https://clinicaltrials.gov/show/NCT00305188

Keywords

Versions (1)
  1. 5/3/17 5/3/17 -
Uploaded on

May 3, 2017

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

  • Newest
  • Oldest
  • Popular
  • Newest
    • Newest
    • Oldest
    • Popular

No comments

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Metastases NCT00305188

English

Eligibility Metastases NCT00305188

1 forms  
  1. StudyEvent: Eligibility
    1. Eligibility Metastases NCT00305188
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
main inclusion criteria :
Description

Inclusion criteria Main

Data type

boolean

Alias
UMLS CUI [1,1]
C1512693
UMLS CUI [1,2]
C1542147
histologically or cytologically-proven metastatic cancer of the colon or rectum.
Description

Secondary malignant neoplasm of colon | Secondary malignant neoplasm of rectum

Data type

boolean

Alias
UMLS CUI [1]
C0346974
UMLS CUI [2]
C0346975
metastatic disease not amenable to potentially curative treatment (eg: inoperable metastatic disease).
Description

Neoplasm Metastasis Curative treatment Unsuccessful | Neoplasm Metastasis Inoperable

Data type

boolean

Alias
UMLS CUI [1,1]
C0027627
UMLS CUI [1,2]
C1273390
UMLS CUI [1,3]
C1272705
UMLS CUI [2,1]
C0027627
UMLS CUI [2,2]
C0205187
male or female aged >18 years.
Description

Age

Data type

boolean

Alias
UMLS CUI [1]
C0001779
who performance status (ps) : 0 or 1.
Description

WHO performance status scale

Data type

boolean

Alias
UMLS CUI [1]
C1298650
measurable disease.
Description

Measurable Disease

Data type

boolean

Alias
UMLS CUI [1]
C1513041
no prior chemotherapeutic regimen for metastatic disease.
Description

Neoplasm Metastasis | Chemotherapy Regimen Absent

Data type

boolean

Alias
UMLS CUI [1]
C0027627
UMLS CUI [2,1]
C0392920
UMLS CUI [2,2]
C0332197
disease-free interval from end of adjuvant therapy of at least 6 months (1 year if oxaliplatin was part of the adjuvant therapy).
Description

Adjuvant therapy | oxaliplatin | Interval Disease Free of

Data type

boolean

Alias
UMLS CUI [1]
C0677850
UMLS CUI [2]
C0069717
UMLS CUI [3,1]
C1272706
UMLS CUI [3,2]
C0012634
UMLS CUI [3,3]
C0332296
prior radiotherapy is permitted if it was not administered to target lesions identified for this study - unless progression within the radiation portal is documented - and provided it has been completed at least 3 weeks before randomization.
Description

Therapeutic radiology procedure Completed | Clinical Trial Target Lesion Excluded

Data type

boolean

Alias
UMLS CUI [1,1]
C1522449
UMLS CUI [1,2]
C0205197
UMLS CUI [2,1]
C0008976
UMLS CUI [2,2]
C2986546
UMLS CUI [2,3]
C2828389
signed written informed consent prior to study entry.
Description

Informed Consent

Data type

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
main exclusion criteria :
Description

Exclusion Criteria Main

Data type

boolean

Alias
UMLS CUI [1,1]
C0680251
UMLS CUI [1,2]
C1542147
any condition or past medical history that contra-indicates treatment with oxaliplatin and 5-fu, as reported in approved labeling information.
Description

Medical contraindication Oxaliplatin | Medical contraindication 5-FU

Data type

boolean

Alias
UMLS CUI [1,1]
C1301624
UMLS CUI [1,2]
C0069717
UMLS CUI [2,1]
C1301624
UMLS CUI [2,2]
C0016360
received chemotherapeutic agents other than 5-fu, lv, levamisole, irinotecan, capecitabine, oxaliplatin as part of adjuvant therapy.
Description

Chemotherapeutic Agents | Fluorouracil | Leucovorin | Levamisole | irinotecan | capecitabine | oxaliplatin | Adjuvant therapy

Data type

boolean

Alias
UMLS CUI [1]
C0003392
UMLS CUI [2]
C0016360
UMLS CUI [3]
C0023413
UMLS CUI [4]
C0023556
UMLS CUI [5]
C0123931
UMLS CUI [6]
C0671970
UMLS CUI [7]
C0069717
UMLS CUI [8]
C0677850
peripheral neuropathy >grade 1.
Description

Peripheral Neuropathy CTCAE Grades

Data type

boolean

Alias
UMLS CUI [1,1]
C0031117
UMLS CUI [1,2]
C1516728
concomitant treatments with drugs/ingredients reported to have a potential activity in preventing peripheral sensory neuropathy.
Description

Pharmaceutical Preparations Preventing Peripheral sensory neuropathy | Pharmaceutical Preparation Ingredient Preventing Peripheral sensory neuropathy

Data type

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C1292733
UMLS CUI [1,3]
C0151313
UMLS CUI [2,1]
C0013227
UMLS CUI [2,2]
C1550600
UMLS CUI [2,3]
C1292733
UMLS CUI [2,4]
C0151313
concurrent active cancer originating from a primary site other than colon or rectum.
Description

Malignant Neoplasm | Anatomic Site Colorectal Excluded

Data type

boolean

Alias
UMLS CUI [1]
C0006826
UMLS CUI [2,1]
C1515974
UMLS CUI [2,2]
C0555952
UMLS CUI [2,3]
C2828389
presence of any symptom suggesting brain metastasis.
Description

Symptoms Metastatic malignant neoplasm to brain Suggestive of

Data type

boolean

Alias
UMLS CUI [1,1]
C1457887
UMLS CUI [1,2]
C0220650
UMLS CUI [1,3]
C0332299
Back to the top of the page

Similar models

Eligibility Metastases NCT00305188

1 forms
  1. StudyEvent: Eligibility
    1. Eligibility Metastases NCT00305188
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Inclusion criteria Main
Item
main inclusion criteria :
boolean
C1512693 (UMLS CUI [1,1])
C1542147 (UMLS CUI [1,2])
Secondary malignant neoplasm of colon | Secondary malignant neoplasm of rectum
Item
histologically or cytologically-proven metastatic cancer of the colon or rectum.
boolean
C0346974 (UMLS CUI [1])
C0346975 (UMLS CUI [2])
Neoplasm Metastasis Curative treatment Unsuccessful | Neoplasm Metastasis Inoperable
Item
metastatic disease not amenable to potentially curative treatment (eg: inoperable metastatic disease).
boolean
C0027627 (UMLS CUI [1,1])
C1273390 (UMLS CUI [1,2])
C1272705 (UMLS CUI [1,3])
C0027627 (UMLS CUI [2,1])
C0205187 (UMLS CUI [2,2])
Age
Item
male or female aged >18 years.
boolean
C0001779 (UMLS CUI [1])
WHO performance status scale
Item
who performance status (ps) : 0 or 1.
boolean
C1298650 (UMLS CUI [1])
Measurable Disease
Item
measurable disease.
boolean
C1513041 (UMLS CUI [1])
Neoplasm Metastasis | Chemotherapy Regimen Absent
Item
no prior chemotherapeutic regimen for metastatic disease.
boolean
C0027627 (UMLS CUI [1])
C0392920 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
Adjuvant therapy | oxaliplatin | Interval Disease Free of
Item
disease-free interval from end of adjuvant therapy of at least 6 months (1 year if oxaliplatin was part of the adjuvant therapy).
boolean
C0677850 (UMLS CUI [1])
C0069717 (UMLS CUI [2])
C1272706 (UMLS CUI [3,1])
C0012634 (UMLS CUI [3,2])
C0332296 (UMLS CUI [3,3])
Therapeutic radiology procedure Completed | Clinical Trial Target Lesion Excluded
Item
prior radiotherapy is permitted if it was not administered to target lesions identified for this study - unless progression within the radiation portal is documented - and provided it has been completed at least 3 weeks before randomization.
boolean
C1522449 (UMLS CUI [1,1])
C0205197 (UMLS CUI [1,2])
C0008976 (UMLS CUI [2,1])
C2986546 (UMLS CUI [2,2])
C2828389 (UMLS CUI [2,3])
Informed Consent
Item
signed written informed consent prior to study entry.
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Exclusion Criteria Main
Item
main exclusion criteria :
boolean
C0680251 (UMLS CUI [1,1])
C1542147 (UMLS CUI [1,2])
Medical contraindication Oxaliplatin | Medical contraindication 5-FU
Item
any condition or past medical history that contra-indicates treatment with oxaliplatin and 5-fu, as reported in approved labeling information.
boolean
C1301624 (UMLS CUI [1,1])
C0069717 (UMLS CUI [1,2])
C1301624 (UMLS CUI [2,1])
C0016360 (UMLS CUI [2,2])
Chemotherapeutic Agents | Fluorouracil | Leucovorin | Levamisole | irinotecan | capecitabine | oxaliplatin | Adjuvant therapy
Item
received chemotherapeutic agents other than 5-fu, lv, levamisole, irinotecan, capecitabine, oxaliplatin as part of adjuvant therapy.
boolean
C0003392 (UMLS CUI [1])
C0016360 (UMLS CUI [2])
C0023413 (UMLS CUI [3])
C0023556 (UMLS CUI [4])
C0123931 (UMLS CUI [5])
C0671970 (UMLS CUI [6])
C0069717 (UMLS CUI [7])
C0677850 (UMLS CUI [8])
Peripheral Neuropathy CTCAE Grades
Item
peripheral neuropathy >grade 1.
boolean
C0031117 (UMLS CUI [1,1])
C1516728 (UMLS CUI [1,2])
Pharmaceutical Preparations Preventing Peripheral sensory neuropathy | Pharmaceutical Preparation Ingredient Preventing Peripheral sensory neuropathy
Item
concomitant treatments with drugs/ingredients reported to have a potential activity in preventing peripheral sensory neuropathy.
boolean
C0013227 (UMLS CUI [1,1])
C1292733 (UMLS CUI [1,2])
C0151313 (UMLS CUI [1,3])
C0013227 (UMLS CUI [2,1])
C1550600 (UMLS CUI [2,2])
C1292733 (UMLS CUI [2,3])
C0151313 (UMLS CUI [2,4])
Malignant Neoplasm | Anatomic Site Colorectal Excluded
Item
concurrent active cancer originating from a primary site other than colon or rectum.
boolean
C0006826 (UMLS CUI [1])
C1515974 (UMLS CUI [2,1])
C0555952 (UMLS CUI [2,2])
C2828389 (UMLS CUI [2,3])
Symptoms Metastatic malignant neoplasm to brain Suggestive of
Item
presence of any symptom suggesting brain metastasis.
boolean
C1457887 (UMLS CUI [1,1])
C0220650 (UMLS CUI [1,2])
C0332299 (UMLS CUI [1,3])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial